Trial · NCT04062123

Memory & Conditioning Under Anesthesia

NCT04062123, Phase 1, Completed, Keith M Vogt; results first posted 2025-04-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Memory & Conditioning Under Anesthesia. Trials, record NCT04062123. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04062123

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Memory & Conditioning Under Anesthesia
NCT number: NCT04062123
Status: Completed
Phases: Phase 1
Enrollment: 92 participants, actual
Lead sponsor: Keith M Vogt
Conditions: Anesthesia, Pain
Interventions: Dexmedetomidine, Propofol, Fentanyl, Peripheral Nerve Stimulation, Placebo
First posted: 2019-08-20
Last updated: 2025-04-18
Results first posted: 2025-04-18

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Explicit Memory Performance	24-hrs post-experiment	Recognition memory testing, using the Remember-Know procedure, in which subjects indicate whether they recognize previously experienced experimental items among novel items (not previously in the experiment). This allows calculation of interdependent measures of recollection \& familiarity using the signal detection statistic, d'. d' is calculated as the cumulative Gaussian distribution of false positive responses subtracted from the cumulative Gaussian distribution of correctly identified previously-experienced items. d' is on a (theoretically infinite) scale of standard deviation units, with negative values representing performance worse than chance guessing and positive values representing stand deviations of performance above chance.
Secondary	Brain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition	Immediately after each experimental item	The Z-score is calculated by linear regression of the task timing against the MRI signal time-course (MRI data is in arbitrary units with no maximum or minimum) at each voxel (single data point in brain). The outcome is listed for the hippocampus, but similar scores are calculated throughout the brain. Z-score of 0 indicates no task-related changes. Z-scores further from zero indicate a larger difference in brain activity, with positive values indicating decreases under the drug condition, while negative Z-scores indicate increases under drug, compared to control. This outcome is reported as a number, as it is calculated using all the data across subjects combined into one statistical measure for the overall strength of difference in MRI signal change between two groups of data. Dispersion measures cannot be calculated for the summary Z-score.
Secondary	Heart Rate Response	Immediately after each experimental item	Heart rate changes (measured by electrocardiogram, EKG) were planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in the peak of the EKG response (R-wave), allowing calculation of instantaneous heart rate. Increases in heart rate are well-known to correlate to sympathetic nervous system activity increases.
Secondary	Skin Response	Immediately after each experimental item	Electrodermal activity (galvanic skin) response was planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in electrodermal activity, measured from the palm of subjects' hand. this well-established measure indicates sweat gland activity and is correlated to sympathetic nervous system activity increases.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Explicit Memory Performance	24-hrs post-experiment		units on a scale	MEAN
SECONDARY	Brain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition	Immediately after each experimental item		Z-score for difference	NUMBER
SECONDARY	Heart Rate Response	Immediately after each experimental item	Acquisition of EKG data was not possible in the scanner, due to interference from the magnetic field. This is why the outcome cannot be reported.
SECONDARY	Skin Response	Immediately after each experimental item	Acquisition of skin conductance data was not possible in the scanner, due to interference from the magnetic field. This is why the outcome cannot be reported.

Source ClinicalTrials.gov

Results by group7

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Explicit Memory Performance	Placebo Control	1.16	95% Confidence Interval 0.97 to 1.34	units on a scale
Explicit Memory Performance	Propofol	.51	95% Confidence Interval 0.182 to 0.842	units on a scale
Explicit Memory Performance	Dexmedetomidine	1.04	95% Confidence Interval 0.73 to 1.35	units on a scale
Explicit Memory Performance	Fentanyl	.98	95% Confidence Interval 0.68 to 1.28	units on a scale
Brain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition	Propofol	3.8		Z-score for difference
Brain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition	Dexmedetomidine	-4.9		Z-score for difference
Brain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition	Fentanyl	-5.0		Z-score for difference

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Propofol	30
Overall Study	STARTED	Dexmedetomidine	29
Overall Study	STARTED	Fentanyl	33
Overall Study	COMPLETED	Propofol	30
Overall Study	COMPLETED	Dexmedetomidine	28
Overall Study	COMPLETED	Fentanyl	33
Overall Study	NOT COMPLETED	Propofol	0
Overall Study	NOT COMPLETED	Dexmedetomidine	1
Overall Study	NOT COMPLETED	Fentanyl	0

Source ClinicalTrials.gov

Adverse events3

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	nausea	Gastrointestinal disorders	Propofol	0	30	0
other	nausea	Gastrointestinal disorders	Dexmedetomidine	0	29	0
other	nausea	Gastrointestinal disorders	Fentanyl	2	33	2

Source ClinicalTrials.gov

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Propofol	0	30
Total, all-cause mortality	Dexmedetomidine	0	29
Total, all-cause mortality	Fentanyl	0	33
Total, other adverse events	Propofol	0	30
Total, other adverse events	Dexmedetomidine	0	29
Total, other adverse events	Fentanyl	2	33
Total, serious adverse events	Propofol	0	30
Total, serious adverse events	Dexmedetomidine	0	29
Total, serious adverse events	Fentanyl	0	33

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants2

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
R35GM146822	Neuroimaging to identify the neural correlates of anesthetic and analgesic action in humans	VOGT, KEITH MICHAEL	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES	2022 to 2025	NIH RePORTER
K23GM132755	Anesthestic modulation of human memory during acute pain	VOGT, KEITH MICHAEL	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES	2019 to 2021	NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as
Remember and Know Test	Primary outcome

Source ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04062123

GET https://conductscience.org/api/trials/v1/NCT04062123/registered

API reference For AI assistants